Episode Details

Seniors in the U.S. are paying way more for prescription drugs than citizens in 19 other developed nations, with prices soaring 81% on average for top 25 drugs—while those same drugs dropped 13% abroad. Enbrel alone jumped 873% here versus a 27% drop overseas. With a key federal subsidy ending after 2026, Medicare Part D premiums could spike 24% by 2027, hitting beneficiaries hard—especially those on standalone plans facing $16+ monthly hikes. While Medicare’s new drug price negotiations (starting with 10 drugs this year) offer some relief, it’s unclear if they’ll fully counteract the coming cost surge. For seniors and their families, understanding these shifts is critical as enrollment decisions loom this fall.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/f5e0cfa57a2da714